These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 113332)

  • 1. Assessing medical efficacy:a neglected administrative necessity.
    Hofmann PB
    Hosp Prog; 1979 Oct; 60(10):45-7. PubMed ID: 113332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical necessity: trying to reach consensus.
    Phillips L
    Hosp Technol Ser; 1996 May; 15(6):5, 10. PubMed ID: 10158519
    [No Abstract]   [Full Text] [Related]  

  • 3. Marketplace. Assessing medical innovations: how health plans pick what technology to cover.
    Moskowitz DB
    Faulkner Grays Med Health; 1997 May; 51(21):suppl 2 p.. PubMed ID: 10167124
    [No Abstract]   [Full Text] [Related]  

  • 4. Policy formulation and technology assessment.
    Banta HD; Behney CJ
    Milbank Mem Fund Q Health Soc; 1981; 59(3):445-79. PubMed ID: 6792555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare coverage for technological innovations.
    Hart S
    N Engl J Med; 2004 Aug; 351(7):719-20; author reply 719-20. PubMed ID: 15309749
    [No Abstract]   [Full Text] [Related]  

  • 6. Technology assessment and coverage decision making.
    McGivney WT
    AAPPO J; 1994; 4(5):11-2, 14-7. PubMed ID: 10150666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of medical practices. The case for technology assessment.
    Fineberg HV; Hiatt HH
    N Engl J Med; 1979 Nov; 301(20):1086-91. PubMed ID: 114833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sounding Boards. What is CBA/CEA, and why are they doing this to us?
    Fuchs VR
    N Engl J Med; 1980 Oct; 303(16):937-8. PubMed ID: 6774250
    [No Abstract]   [Full Text] [Related]  

  • 9. A primer on the assessment of medical technologies.
    Matuszewski KA
    Pharm Pract Manag Q; 1997 Jan; 16(4):53-65. PubMed ID: 10164160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic approach to rationing health care resources.
    Hicks LL; Boles KE
    Case Stud Health Adm; 1985; 5():1-133. PubMed ID: 10313476
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trials of cost effectiveness in technology evaluation.
    Valk PE
    Q J Nucl Med; 2000 Jun; 44(2):197-203. PubMed ID: 10967629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimbursement disputes involving experimental medical treatment.
    Molino PJ
    J Health Hosp Law; 1991 Nov; 24(11):329-36, 343, 359. PubMed ID: 10114834
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment and approval of medical devices used in diagnostic imaging in the United States.
    Johnson GC
    Isr J Med Sci; 1986; 22(7-8):505-18. PubMed ID: 3536797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical context of technology assessment.
    Smits HL
    J Health Polit Policy Law; 1984; 9(l):31-40. PubMed ID: 11650667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic evaluation: in need of more analytical rigor or more practical relevance?
    Rovithis D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):107-10. PubMed ID: 19402796
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer therapy: reimbursement of new therapeutic technologies.
    Williams HM
    Yale J Biol Med; 1992; 65(2):83-97. PubMed ID: 1519380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.